According to research, Tirzepatide may reduce body weight more significantly than Semaglutide. Those using Tirzepatide at the highest dosage lost an average of 21% of their body weight throughout the course of a 72-week study. In contrast, the placebo group experienced a 3% loss.
Tirzepatide belongs to a recently discovered class of medications known as GLP-1 receptor agonists, which were created to treat type 2 diabetes. In addition to lowering blood sugar, the medications caused patients to lose weight, therefore pharmaceutical companies developed special combinations to aid in weight loss.
Both Tirzepatide and Semaglutide are both Type 2 diabetes medications that can also assist people with weight loss. However, a recent study shows that Tirzepatide is more effective when it comes to weight loss.
A recent study comparing the efficacy of Tirzepatide and Semaglutide in persons with obesity or overweight was published in JAMA Internal Medicine.
The researchers discovered that although tirzepatide and semaglutide both caused weight loss, tirzepatide was more successful.
This study broadens our understanding of these weight-loss drugs by providing crucial new information, which could eventually help shape therapeutic standards.
Download GMP-Certified API Product List
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations. Click here to download our complete API product list.
Get your requested raw materials quotation
Table of Contents
What is Tirzepatide?
Adults with type 2 diabetes who are having trouble losing weight are prescribed pirzepatide, which is sold under the brand names Zepbound and Mounjaro. Tirzepatide, a GIP and GLP-1 receptor agonist, decreases appetite and slows the movement of food from the stomach into the small intestine, which aids in weight loss.
You might feel fuller for longer as a result of this. By reducing the quantity of sugar the liver produces and increasing the synthesis of insulin, pirzepatide also reduces blood sugar levels.
For people who are obese or overweight and have weight-related medical issues like hypertension or cardiovascular disease, Zepbound has FDA approval. To help you lose weight and keep it off, Zepbound should be used in conjunction with diet and exercise.
Tirzepatide mimics the hormone GLP-1, which is known to regulate hunger, by acting as a glucagon-like-peptide-1 (GLP-1) receptor agonist, which makes people eat less. Moreover, it mimics the GIP (glucose-dependent insulinotropic polypeptide) hormone. It is commonly known that this hormone causes blood glucose levels to rise, which may cause feelings of fullness.
Additionally, tirzepatide slows down the speed at which food moves through the intestines, increasing the amount of time food stays in the stomach and contributing to a sensation of contentment and fullness.
Tirzepatide may also boost energy, which could result in more frequent calorie burning throughout the day.
Tirzepatide was approved for the treatment of diabetes in the United States in May 2022, in the European Union in September 2022, in Canada in November 2022, and in Australia in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. It was approved by the FDA for weight loss in November 2023
Tirzepatide has side effects that are comparable to those of dulaglutide and other well-known GLP-1 receptor agonists. The gastrointestinal system is where most of these impacts take place. Adverse reactions include nausea, vomiting, diarrhoea, decreased appetite, constipation, upper abdominal discomfort, and stomach pain are among the most reported side effects.
Get your requested raw materials quotation
Tirzepatide vs Semaglutide
Tirzepatide may reduce body weight more significantly than Semaglutide, according to research. Those using Tirzepatide at the highest dosage lost an average of 21% of their body weight throughout the course of a 72-week study. In contrast, the placebo group experienced a 3% loss.
Research on Semaglutide’s effectiveness has also shown promise. After three months and six months, participants who were overweight or obese and took the drug dropped an average of 5.9% and 10.9% of their body weight, respectively.
Since Terzepatide targets both the GLP-1 and GIP receptors but Semaglutide solely targets the GLP-1 receptor, it is possible that this contributes to the more notable weight reduction observed with Terzepatide.
Although both Tirzepatide and Semaglutide are drugs that help with long-term weight control, further comparison research is required to make definitive conclusions. It’s also critical to keep in mind that every person has a unique reaction to drugs. For certain individuals, semaglutide may be more effective than tirzepatide.
Want to buy GMP API pharmaceutical ingredients?
MedicaPharma ensures access to GMP active pharmaceutical ingredients across multiple resilient global supply chains. Click here to view a full GMP API product list.
MedicaPharma is capable of supplying all GMP materials needed; our experience with sourcing materials that are difficult to obtain makes us the ultimate choice; just challenge us, we will find any material you need.
Get a Fast and Easy GMP-Certified API Quote
Focus on your compounding pharmacy business and let MedicaPharma take care of your APIs. Obtaining a quote is easy
